MedTrace Logo

A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza A

NCT06205641 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 584

Last updated 2024-01-16

No results posted yet for this study

Summary

This study is a prospective, multicenter, randomized controlled trial and aims to evaluate efficacy and safety of Xuanfei Baidu Granule in the treatment of influenza A.

This study plans to enroll 584 subjects. The subjects will be randomly divided into 4 groups according to the ratio of 1:1:1:1, and they will be treated with Xuanfei Baidu Granule Placebo, Xuanfei Baidu Granule, Xuanfei Baidu Granule combined with Baloxavir Marboxil tablet.1 bag of Xuanfei Baidu Granule and Xuanfei Baidu Granule Placebo in the morning and evening, and take with boiling water for 5 days. Baloxavir Marboxil Tablet was taken orally 2 tablets, once a day for 1 day.

The subjects were visited every day for 7 days after enrollment.

Conditions

Interventions

DRUG

Xuanfei Baidu Granule Placebo

Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.

DRUG

Xuanfei Baidu Granule

Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.

DRUG

Baloxavir Marboxil Tablet

Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2024-06-30
Completion
2025-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06205641 on ClinicalTrials.gov